ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Hansoh Pharmaceutical Group and GNI Group side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Hansoh Pharmaceutical GroupGNI Group
studies on the registry19026
open to participants now1177
phase 3 studies under way214
reach primary completion within a year272
programswith a study of their own in two years424

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseHansoh Pharmaceutical GroupGNI Group
Phase 1

Hansoh Pharmaceutical Group: 19 of its 42 programs at phase 1

  1. HS-20122phase 1
  2. HS-20136-2phase 1
  3. PARP1 Inhibitor HS-10502phase 1
  4. Alveltamigphase 1
  5. apatinibphase 1

and 14 more — sign in to see them all

45%

GNI Group: 2 of its 4 programs at phase 1

  1. F230 tabletsphase 1
  2. tenofovir amibufenamidephase 1
50%
Phase 2

Hansoh Pharmaceutical Group: 9 of its 42 programs at phase 2

  1. HS-20118phase 2
  2. HIF-2alpha Inhibitor HS-10516phase 2
  3. HS-10390phase 2
  4. HS-10542phase 2
  5. RET Inhibitor HS-10365phase 2

and 4 more — sign in to see them all

21%
00%
Phase 3

Hansoh Pharmaceutical Group: 13 of its 42 programs at phase 3

  1. risvutatug rezetecanphase 3
  2. HS-10504phase 3
  3. HS-10506phase 3
  4. aumolertinibphase 3
  5. mocertatug rezetecanphase 3

and 8 more — sign in to see them all

31%

GNI Group: 2 of its 4 programs at phase 3

  1. hydronidonephase 3
  2. pirfenidonephase 3
50%
Approved, new studies

Hansoh Pharmaceutical Group: 1 of its 42 programs at approved, new studies

  1. tenofovir amibufenamideapproved, new study
2%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Hansoh Pharmaceutical Group15 readouts · 2 phase 3

Hansoh Pharmaceutical Group, Nov ’26: 1 program whose next study reaches primary completion

  1. HS-10504phase 3 · Nov 19 · NCT07685041

Hansoh Pharmaceutical Group, Dec ’26: 4 programs whose next study reaches primary completion

  1. HS-20118phase 2 · Dec 25 · NCT07896915
  2. risvutatug rezetecanphase 3 · Dec 30 · NCT06699576
  3. Anti-CDH17 Antibody-drug Conjugate HS-20110phase 2 · Dec 31 · NCT06892379
  4. HS-20136-2phase 1 · Dec 31 · NCT07483437

Hansoh Pharmaceutical Group, Jan ’27: 2 programs whose next study reaches primary completion

  1. HS-20152phase 1 · Jan 1 · NCT07503015
  2. HS-10522phase 1 · Jan 20 · NCT07609875

Hansoh Pharmaceutical Group, Feb ’27: 1 program whose next study reaches primary completion

  1. Embibatinibphase 3 · Feb 0 · NCT07933224

Hansoh Pharmaceutical Group, Mar ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. HS-20137phase 3 · Mar 1 · NCT07879885
  2. mocertatug rezetecanphase 3 · Mar 7 · NCT06855069
  3. olatorepatidephase 3 · Mar 30 · NCT07156500
·

Hansoh Pharmaceutical Group, May ’27: 2 programs whose next study reaches primary completion

  1. HS-10542phase 2 · May 30 · NCT07470762
  2. HS-10582phase 1 · May 30 · NCT07777003
·

Hansoh Pharmaceutical Group, Jul ’27: 1 program whose next study reaches primary completion

  1. HIF-2alpha Inhibitor HS-10516phase 2 · Jul 10 · NCT07097935

Hansoh Pharmaceutical Group, Aug ’27: 1 program whose next study reaches primary completion

  1. RET Inhibitor HS-10365phase 2 · Aug 31 · NCT06147570
··
GNI Group2 readouts · 1 phase 3·

GNI Group, Dec ’26: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. hydronidonephase 3 · Dec 1 · NCT07262333
  2. pirfenidonephase 3 · Dec 30 · NCT07388680
··········
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Hansoh Pharmaceutical Group

New programs 1

  • HS-20197phase 1 · first study · Sep 10

Reached a new phase 2

Study stopped 0

None

Primary completion later 0

None

GNI Group

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.

ConditionHansoh Pharmaceutical GroupGNI Group
Hepatitis B, Chronicboth · compare here

Hansoh Pharmaceutical Group in Hepatitis B, Chronic: 1 program

  1. tenofovir amibufenamideapproved, new study

Their studies: Hansoh Pharmaceutical Group’s studies of Hepatitis B, Chronic in search

GNI Group in Hepatitis B, Chronic: 2 programs

  1. hydronidonephase 3
  2. tenofovir amibufenamidephase 1

Their studies: GNI Group’s studies of Hepatitis B, Chronic in search

Renal Insufficiency, Chronicboth · compare here

Hansoh Pharmaceutical Group in Renal Insufficiency, Chronic: 1 program

  1. HS-10390phase 2

Their studies: Hansoh Pharmaceutical Group’s studies of Renal Insufficiency, Chronic in search

GNI Group in Renal Insufficiency, Chronic: 1 program

  1. hydronidonephase 3

Their studies: GNI Group’s studies of Renal Insufficiency, Chronic in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Hansoh Pharmaceutical Group 29 of 42 · GNI Group 0 of 4 programs (9 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.